Description
Kyprolis (carfilzomib) is a proteasome inhibitor listed in our Cancer medications directory and prescribed for specified blood or lymphatic cancers (1.1) (2.1). administered via the intravenous route, Kyprolis is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Kyprolis is a medication containing the active pharmaceutical ingredient carfilzomib, classified pharmacologically as a proteasome inhibitor (2.1). It is clinically indicated for the management of specified blood or lymphatic cancers as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the Cancer medications section of our catalogue, patients and prescribers frequently review Kyprolis alongside related therapies such as Avastin (Bevacizumab), Besponsa (Inotuzumab ozogamicin), Cyclophosphamide, and Cytoxan (Cyclophosphamide).
Official Indications and Usage
Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. (1.1)
Mechanism of Action and Pharmacology
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors. (1.1)
What are Blood and lymphatic cancers?
Leukemia, lymphoma, and multiple myeloma are different cancers involving blood-forming or immune cells. Their medicine regimens are diagnosis-specific. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Blood and lymphatic cancers condition guide for appointment questions and related therapies (2.1).
Ordering Kyprolis from Canada for U.S. Delivery
U.S. patients can order Kyprolis (Carfilzomib) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax (844) 666 – 6819.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$14.99 USD Tracked Parcel
- Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Kyprolis |
| Chemical / Generic Name | Carfilzomib |
| Pharmacological Class | Proteasome Inhibitor |
| Therapeutic Category | Cancer medications |
| Molecular Formula | C40H57N5O7 (2.1) |
| Molecular Weight | 719.9. g/mol (2.1) |
| Protein Binding | ~97% (1.1) |
| Elimination Half-Life | ~1 hour (1.1) |
| Legal Status | Rx-Only (Prescription Required) |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus |
| Routes of Administration | Intravenous |
| Dosage Forms & Strengths | For injection: 10 mg, 30 mg and 60 mg as a white to off-white lyophilized cake or powder in single-dose vial for reconstitution. For injection: 10 mg, 30 |
| Primary Indications | Specified Blood Or Lymphatic Cancers |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| FDA UNII Identifier | 72X6E3J5AR |
| NLM RxNorm Concept ID (RxCUI) | 1806934, 1806937, 1806940, 1806942 |
| FDA Application License | NDA202714 |
| Official DailyMed SetID | ea66eb30-e665-4693-99a1-a9d3b4bbe2d6 |
| Catalogue Index Links | Letter K Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
Hydrate prior to and following Kyprolis as needed. Premedicate prior to all Cycle 1 doses and if infusion-related reactions develop or reappear. The recommended dosing regimens are as follows. Regimen Dosage Infusion Time Kyprolis and Dexamethasone (Kd) or Kyprolis, Daratumumab and Dexamethasone (DKd) or Kyprolis, Daratumumab and hyaluronidase-fihj and Dexamethasone (DKd) 20/70 mg/m 2 once weekly 30 minutes Kyprolis and Dexamethasone (Kd) or Kyprolis, Daratumumab and Dexamethasone (DKd) or Kyprolis, Daratumumab and hyaluronidase-fihj and Dexamethasone (DKd) or Kyprolis, Isatuximab and Dexamethasone (Isa-Kd) or Kyprolis Monotherapy 20/56 mg/m 2 twice weekly 30 minutes Kyprolis, Lenalidomide and Dexamethasone (KRd) or Kyprolis Monotherapy 20/27 mg/m 2 twice weekly 10 minutes. (1.1)
Presentations and Strengths
For injection: 10 mg, 30 mg and 60 mg as a white to off-white lyophilized cake or powder in single-dose vial for reconstitution. (1.1)
Administration Guidance
Administer Kyprolis by injection or infusion (Intravenous) strictly according to your prescriber’s individualized dosing schedule (1.1). Always verify the concentration, vial or pen presentation, and dose markings prior to administration, rotate injection sites when self-injecting subcutaneously, and never share injection pens, needles, or syringes between patients.
Missed Dose Guidance
If you miss a scheduled dose of Kyprolis, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Kyprolis is carfilzomib (2.1).
Excipients and Formulation Carriers
Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).
Cautions and important safety information
Contraindications
None. (1.1)
Key Clinical Precautions
Before starting or continuing Kyprolis, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):
- Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
- Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
- Gastrointestinal ulceration, bleeding, and perforation: Serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines can occur with or without warning symptoms.
- Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
- Hemorrhage and bleeding risk: Anticoagulant, antiplatelet, or gastrointestinal-affecting therapies can increase the risk of serious or fatal bleeding. Report unusual bruising, nosebleeds, blood in urine or stools, black tarry stools, or coughing up blood immediately.
- Renal function and acute kidney injury: Changes in serum creatinine or estimated glomerular filtration rate (eGFR) can occur, particularly in patients with volume depletion, chronic kidney disease, or concomitant use of NSAIDs, ACE inhibitors, ARBs, or diuretics. Renal function should be assessed prior to initiation and periodically thereafter.
Pregnancy, Lactation, and Special Populations
Kyprolis can cause fetal harm based on findings from animal studies and its mechanism of action. There are no available data on Kyprolis use in pregnant women to evaluate for drug-associated risks. Kyprolis caused embryo-fetal lethality in rabbits at doses lower than the clinical dose. Advise pregnant women of the potential risk to the fetus. In the U.S. General population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. (1.1)
Interactions
Always provide your prescribing physician and pharmacist with an up-to-date list of all prescription medications, over-the-counter products, vitamins, and herbal supplements you take before starting Kyprolis (2.1).
Side effects
Like all medications, Kyprolis can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):
- Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; eating smaller, lower-fat meals and avoiding lying down immediately after eating may help reduce nausea.
- Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
- Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
- Constipation: Adequate hydration and dietary fiber can help manage mild changes in bowel habits.
- Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
- Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
Clinical Trial and Postmarketing Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Toxicities Acute Renal Failure Tumor Lysis Syndrome Pulmonary Toxicity Pulmonary Hypertension Dyspnea Hypertension Venous Thrombosis Infusion-Related Reactions Hemorrhage Thrombocytopenia Hepatic Toxicity and Hepatic Failure Thrombotic Microangiopathy Posterior Reversible Encephalopathy Syndrome Progressive Multifocal Leukoencephalopathy The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral. The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in the combination therapy trials: anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, and insomnia. (1.1)
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Storage and Handling Unopened vials should be stored refrigerated 2°C to 8°C (36°F to 46°F). Retain in original package to protect from light. (1.1)
Store Kyprolis in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).
Frequently Asked Questions About Kyprolis
What is Kyprolis and what active ingredient does it contain?
Kyprolis is a proteasome inhibitor containing the active pharmaceutical ingredient carfilzomib. It is supplied for intravenous administration and requires a valid prescription where applicable.
How does Kyprolis work in the body?
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors.
What conditions is Kyprolis prescribed to treat?
Kyprolis is primarily indicated for specified blood or lymphatic cancers. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Kyprolis?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Kyprolis is administered via the intravenous route. Administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Kyprolis?
Commonly reported side effects of Kyprolis include feeling sick, vomiting, loose stools, constipation, headache, and dizziness. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.
What medications or substances can interact with Kyprolis?
Share your full list of current prescription medications, over-the-counter products, and supplements with your prescriber and pharmacist so they can screen for any potential drug interactions.
Can Kyprolis be used during pregnancy or breastfeeding?
Official prescribing information highlights pregnancy-related precautions for Kyprolis. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.
Do I need a prescription to buy Kyprolis online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Kyprolis (Carfilzomib) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
Does Kyprolis have a generic equivalent (Carfilzomib) at a Canada pharmacy?
Currently, Kyprolis (Carfilzomib) is dispensed in our catalogue as a brand-name formulation. Check our Carfilzomib active ingredient hub for updates as licensed generic presentations become available.
How is Kyprolis shipped to U.S. residents, and how much does shipping cost?
Kyprolis ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.
How can I send or transfer my Kyprolis prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Kyprolis prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Kyprolis (Carfilzomib) are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Kyprolis (Carfilzomib), Official Prescribing Information. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) MedlinePlus Medical Encyclopedia: Leukemia. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (3.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).
